Brain Tumor Treatments: North Dakota

Sponsored By

Please Click On The Above Banner For More Details

[Click HERE to print this page!]

Search Term: North Dakota
Please scroll down to see the matching trials.

  (0.8351) Brain Tumor Treatments: North Dakota
  (0.7742) Untitled Document
  (0.7742) Brain Tumor Activism
  (0.7742) Letter Writing Wizard
  (0.7742) Brain Tumor Activism

Sorry - There were no pages found that contain that search phrase.


	Treatment	Location	Last Updated

Details	Phase III Trial Comparing Conventional Adjuvant Temozolomide with Dose-intensive Temozolomide in Patients with Newly Dignosed Glioblastoma	Minot, ND USA	04/11/2008

Details	Phase I/II Study of Sorafenib and Temsirolimus in Patients With Recurrent Glioblastoma	Bismarck, ND USA	04/28/2007

Details	Comprehensive Genetic Analysis Of Brain Tumors In Children. (A Non-Therapeutic Study)	Fargo, ND USA	10/12/2006

Details	Erlotinib and Temozolomide With Radiation Therapy in Treating Patients With Glioblastoma Multiforme or Other Brain Tumors	Fargo, ND USA	06/26/2006

Details	Erlotinib and Temozolomide With Radiation Therapy in Treating Patients With Glioblastoma Multiforme or Other Brain Tumors	Bismarck, ND USA	06/26/2006

Details	Phase I/II Trial of Imatinib Mesylate; (Gleevec; ST1571) in Treatment of Recurrent Oligodendroglioma and Mixed Oligoastrocytoma	Bismarck, ND USA	06/26/2006

Details	Vorinostat in Treating Patients With Progressive or Recurrent Glioblastoma Multiforme	Fargo, ND USA	06/26/2006

Details	Vorinostat in Treating Patients With Progressive or Recurrent Glioblastoma Multiforme	Bismarck, ND USA	06/26/2006

Details	Phase I/II Trial of Imatinib Mesylate; (Gleevec; ST1571) in Treatment of Recurrent Oligodendroglioma and Mixed Oligoastrocytoma	Bismarck, ND USA	11/27/2005

Details	Observation or Radiation Therapy and/or Chemotherapy and Second Surgery in Treating Children Who Have Undergone Surgery for Ependymoma	Fargo, ND USA	11/27/2005

Details	A Phase II Study of HLA-Matched Peripheral Blood Stem Cell Transplantation for Metastatic Renal Cell Carcinoma as Adoptive Allogeneic Immunotherapy	Fargo, ND USA	11/06/2005